A Phase 1 interventional study of B/F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Active, not recruiting at 7 sites in 2 countries. Open to participants aged Up to 120 Hours. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study is to learn more about the study drug, Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), safety, tolerability, and pharmacokinetics (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) in neonates exposed to human immunodeficiency virus type 1 (HIV-1).
The primary objective of this study is to evaluate the safety and plasma pharmacokinetics (PK) (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) of B/F/TAF tablet for oral suspension (TOS) in full-term neonates exposed to HIV-1 but uninfected.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Mother inclusion criteria:
Neonate inclusion criteria:
Key Exclusion Criteria:
Mother exclusion criteria:
Neonate exclusion criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Full-term neonate participants, who are exposed to HIV-1 but uninfected, with a weight of ≥ 2.5 kg at birth and their mothers will be assigned to Cohort 1 Group A to evaluate a different pharmacokinetic (PK) sampling scheme than Cohort 1 Group B. Neonate participants will receive a single dose of B/F/TAF fixed-dose combination 1.88/7.5/0.94 mg tablet for oral suspension administered along with 1 antiretroviral as standard of care postnatal prophylaxis at both Visits 1 and 3.
Drug: B/F/TAF
Once enrollment in Cohort 1 Group A is completed, full-term neonate participants, who are exposed to HIV-1 but uninfected, with a weight of ≥ 2.5 kg at birth and their mothers will be assigned to Cohort 1 Group B to evaluate a different PK sampling scheme than Cohort 1 Group A. Participants will receive a single dose of B/F/TAF fixed-dose combination 1.88/7.5/0.94 mg tablet for oral suspension administered along with 1 antiretroviral as standard of care postnatal prophylaxis at both Visits 1 and 3.
Drug: B/F/TAF
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
Tablet for oral suspension administered
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAs) Though Week 8 After Neonate Birth
Time frame: First dose date up to 8 Weeks
Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities Through Week 8 After Neonate Birth
Time frame: First dose date up to 8 Weeks
Pharmacokinetic (PK) parameters for Bictegravir (BIC): AUCinf
AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time.
Time frame: Predose up to 72 hours postdose
PK parameters for BIC: AUClast
AUClast is defined as the area under the concentration versus time curve from time zero to the last quantifiable concentration.
Time frame: Predose up to 72 hours postdose
PK parameters for BIC: AUC0-24h
AUC0-24h is defined as the partial area under the concentration versus time curve from time 0 to time 24 hours.
Time frame: Predose up to 24 hours postdose
PK parameters for BIC: Cmax
Cmax is defined as the maximum observed concentration of drug.
Time frame: Predose up to 72 hours postdose
PK parameters for BIC: Tmax
Tmax is defined as the time (observed time point) of Cmax.
Time frame: Predose up to 72 hours postdose
PK parameters for BIC: Cmin
Cmin is defined as the minimum observed concentration of drug.
Time frame: Predose up to 72 hours postdose
PK parameters for BIC: C24h
C24h is defined as the concentration of drug at time 24 hours.
Time frame: At 24 hours postdose
PK parameters for BIC: t1/2
t1/2 is defined as the terminal elimination half-life.
Time frame: Predose up to 72 hours postdose
PK parameters for BIC: Apparent CL/F
Apparent CL/F is defined as the apparent total body clearance for extravascular administration.
Time frame: Predose up to 72 hours postdose
PK parameters for BIC: Apparent Vz/F
Apparent Vz/F is defined as the apparent volume of distribution based on the terminal phase.
Time frame: Predose up to 72 hours postdose
PK Parameters for Emtricitabine (FTC), and Tenofovir (TFV): AUCinf
AUCinf is defined as the area under the concentration versus time curve extrapolated to infinite time.
Time frame: Predose up to 72 hours postdose
PK parameters for FTC, TAF, and TFV: AUClast
AUClast is defined as the area under the concentration versus time curve from time zero to the last quantifiable concentration.
Time frame: Predose up to 72 hours postdose
PK parameters for FTC, TAF, and TFV: AUC0-24h
AUC0-24h is defined as the partial area under the concentration versus time curve from time 0 to time 24 hours.
Time frame: Predose up to 24 hours postdose
PK parameters for FTC, TAF, and TFV: Cmax
Cmax is defined as the maximum observed concentration of drug.
Time frame: Predose up to 72 hours postdose
PK parameters for FTC, TAF, and TFV: Tmax
Tmax is defined as the time (observed time point) of Cmax.
Time frame: Predose up to 72 hours postdose
PK parameters for FTC, TAF, and TFV: Cmin
Cmin is defined as the minimum observed concentration of drug.
Time frame: Predose up to 72 hours postdose
PK parameters for FTC, TAF, and TFV: C24h
C24h is defined as the concentration of drug at time 24 hours.
Time frame: At 24 hours postdose
PK parameters for FTC, TAF, and TFV: t1/2
t1/2 is defined as the terminal elimination half-life.
Time frame: Predose up to 72 hours postdose
PK parameters for FTC and TAF: Apparent CL/F
Apparent CL/F is defined as the apparent total body clearance for extravascular administration.
Time frame: Predose up to 72 hours postdose
PK parameters for FTC and TAF: Apparent Vz/F
Apparent Vz/F is defined as the apparent volume of distribution based on the terminal phase.
Time frame: Predose up to 72 hours postdose
Mother/Caregiver Reported Acceptability of B/F/TAF tablet for oral suspension (TOS)
Acceptability assessed by a numeric response between numbers 1-5. Higher scores indicate better acceptability.
Time frame: First dose date up to 15 days
Mother/Caregiver Reported Palatability of B/F/TAF tablet for oral suspension (TOS)
Palatability assessed by a numeric response between numbers 1-5. Higher scores indicate better palatability.
Time frame: First dose date up to 15 days
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide